Pipeline
| ID | Technology | API | Therapeutic Area | Administration | Formulation | Pre-clinical | Phase 1 | Phase 2 | Partner |
|---|---|---|---|---|---|---|---|---|---|
| MTX110 | MidaSolve | Panobinostat | Glioblastoma | Direct to tumour via CED | |||||
| MTX110 | MidaSolve | Panobinostat | Brain Cancer in Children (DIPG) | Direct to tumour via CED | |||||
| MTX110 | MidaSolve | Panobinostat | Medulloblastoma | Direct to tumour | |||||
| MTX114 | MidaCore™ | Methotrexate | Psoriasis | Topical | |||||
| MTD211 | Q-Sphera™ | Brexpiprazole | Schizophrenia, MDD | Long Acting Injectable | |||||
| MTD219 | Q-Sphera™ | Tacrolimus | Prophylaxis, transplant rejection | Long Acting injectable | |||||
| MTX213 | Q-Sphera™ | undisclosed | undisclosed | Long Acting Injectable | Janssen | ||||
| MTX223 | Q-Sphera™ | undisclosed | undisclosed | Long Acting Injectable | Janssen | ||||
Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain.
Q-Sphera™
Biodexa Pharmaceuticals Q-Sphera™ technology focusses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics.
In partnership, we use our rapid R&D innovation to enable drugs to reach areas of the body where they are needed and to exert their actions in an tuneable, effective, and precise manner.
MidaCore™
MidaCore™ technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The small size and multi-functional arrangement of molecules around a gold core underpin MidaCore’s ability to improve biodistribution and targeted drug delivery.
MidaSolve
MidaSolve Nano Inclusion technology solubilises potent molecules that have minimal solubility at biological pH extending available routes of administration, including direct-to-tumour delivery.